(Q35212334)

7 August 2017

Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival (English)

1 reference

7 August 2017

1 reference

1 reference

Pratima Sharma

1

1 reference

7 August 2017

Amy Hosmer

2

1 reference

7 August 2017

Henry Appelman

3

1 reference

7 August 2017

Barbara McKenna

4

1 reference

7 August 2017

Mohammad S Jafri

5

1 reference

7 August 2017

Patricia Sullivan

6

1 reference

7 August 2017

Robert J Fontana

7

1 reference

7 August 2017

Anna S Lok

8

1 reference

7 August 2017

1 October 2013

1 reference

7 August 2017

Hepatology international

1 reference

7 August 2017

7

1 reference

7 August 2017

4

1 reference

7 August 2017

990-999

1 reference

https://scigraph.springernature.com/pub.10.1007/s12072-013-9436-1

7 August 2017

0 references

cites work

Altered thymic function during interferon therapy in HCV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Cyclosporin versus tacrolimus for liver transplanted patients

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Long-term outcome of hepatitis C infection after liver transplantation

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver

13 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9436-1

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371864

Viral hepatitis and liver transplantation

26 September 2018

1 reference

12 December 2020

Response to steroids in de novo autoimmune hepatitis after liver transplantation

1 reference

12 December 2020

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

1 reference

12 December 2020

Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation

1 reference

12 December 2020

10.1007/S12072-013-9436-1

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference